東曜(01875.HK)續漲23%曾創五個月高 核心在研新藥TAB008 III期達臨床試驗終點
東曜藥業(01875.HK)核心在研新藥TAB008 III期達臨床試驗預設主要終點,該股連升第五天,今早曾逆市飆升55%高見6.2元,創五個月高遇壓,現造4.95元,續漲近23%,一向薄弱成交增至125萬股。
東曜是內地一間臨床階段仍未有盈利的生物製藥公司,股份去年11月8日以每股6.55元來港上市,掛牌後股價一直「潛水」,首掛日高見6.43元已行人止步。
東曜昨天收市後公布,旗下核心在研產品TAB008的隨機III期臨床試驗最近達到預設主要終點(即是比較TAB008和阿瓦斯汀療效),集團將繼續如期推進TAB008新藥申請。TAB008是一種抗血管內皮細胞生長因子單克隆抗體在研藥物,是目前集團進度最快在研生物藥。另外,該公司昨天(21日)起正式委任劉軍為公司首席運營官,將負責集團運營管理,並協助總經理共同推進海外業務發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.